The combination of Venetoclax (also known as ABT-199) and HHT effectively hindered the proliferation of AML cells with the FLT3–ITD mutation by inducing apoptosis in a dose- and time-dependent manner. Here, FLT3 is linked to acute myeloid leukemia.